Abstract

Nishu, Alok Bhardwaj

ABSTRACT

The treatment options for rheumatoid arthritis (RA) have greatly increased throughout the last 20 years. New biologics, small molecule drugs, promising agents, and emerging safety signals are all covered in this article. With these new options, remission is within reach, and tapering is a vital part of diabetes therapy on a daily basis. Future studies will provide doctors with the best ways for treating rheumatoid arthritis. Patients' quality of life has greatly improved, even if rheumatoid arthritis cannot be cured. Screening programs, comprehensive information on the disease spectrum, and sickness prevention strategies all have the ability to enhance epidemiological metrics. Making a correct diagnosis quickly is crucial for efficient condition management since symptoms can often be associated with other conditions. Accurate use of ACR-EULAR criteria, detection and quantification of diagnostic biomarkers, and correlation with imaging modalities are three of the many components that go into making a proper diagnosis. The end goal of aggressive pharmacological treatment for rheumatoid arthritis (RA) is to achieve full remission or a significant reduction in symptoms and clinical indicators. Rheumatoid arthritis is now manageable because to research that has improved our understanding of the disease's pathophysiological causes and led to the creation of new therapeutic approaches. Novel biologic medications, such as TNF and IL-1 antagonists, and the early prescription of DMARDs have started to alter rheumatologists' therapeutic approaches. As more data is collected from the use of these agents and other, as-yet-undeveloped agents, rheumatologists will likely make additional adjustments to the way they treat this serious disease, both alone and in conjunction with DMARDs. However, many patients still show little improvement with the current treatments, demonstrating the need for new medications and a greater focus on individualised care.